OCT-1 as a determinant of response to an... [Clin Pharmacol Ther. 2011] - PubMed

Save items

loading

Related citations in PubMed

Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. [Pharm Res. 2008]
Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.
Hirayama C, Watanabe H, Nakashima R, Nanbu T, Hamada A, Kuniyasu A, Nakayama H, Kawaguchi T, Saito H. Pharm Res. 2008 Apr; 25(4):827-35. Epub 2007 Oct 13.
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. [Clin Cancer Res. 2008]
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, et al. Clin Cancer Res. 2008 Jan 15; 14(2):352-9.
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate. [Haematologica. 2005]
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Perel JM, McCarthy C, Walker O, Irving I, Williams B, Kennedy GA. Haematologica. 2005 Nov; 90 Suppl:ECR25.
Review Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. [Expert Opin Pharmacother. 2010]
Review Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
Fullmer A, Kantarjian H, Cortes J, Jabbour E. Expert Opin Pharmacother. 2010 Dec; 11(18):3065-72. Epub 2010 Nov 13.
Review Towards a cure for chronic myeloid leukemia: are we there yet? [Semin Hematol. 2010]
Review Towards a cure for chronic myeloid leukemia: are we there yet?
Cortes J. Semin Hematol. 2010 Oct; 47(4):299-301.

See reviews... See all...

Cited by 1 PubMed Central article

Review Contribution of tumoral and host solute carriers to clinical drug response. [Drug Resist Updat. 2012]
Review Contribution of tumoral and host solute carriers to clinical drug response.
Sprowl JA, Mikkelsen TS, Giovinazzo H, Sparreboom A. Drug Resist Updat. 2012 Feb-Apr; 15(1-2):5-20. Epub 2012 Mar 28.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

OCT-1 as a determinant of response to antileukemic treatment.
OCT-1 as a determinant of response to antileukemic treatment.
Clin Pharmacol Ther. 2011 Apr ;89(4):608-11. doi: 10.1038/clpt.2011.12. Epub 2011 Feb 23 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

OCT-1 as a determinant of response to antileukemic treatment.

Source

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 1 PubMed Central article

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information